Introduction
Ovarian cancer (OC) is the most lethal of the gynecological cancers and is the fifth leading cause of death due to cancer in women. Early detection of OC significantly enhances survival; however, most OCs are detected at advanced stages (Tortolero-Luna et al., 1994; Daly and Obrams, 1998) . The majority of OCs arise from the ovarian surface epithelium (OSE), which are modified peritoneal mesothelial cells (Scully, 1995) . A number of growth factors can regulate proliferation of the OSE, including transforming growth factor beta (TGFb), which is synthesized by normal OSE and inhibits its proliferation (Berchuk et al., 1992) .
Active TGFb binds to the TGFb type II receptor subunit (TbRII), which then recruits and activates the type I receptor subunit (TbRI). This active receptor complex phosphorylates and activates the receptor-activated Smads (R-Smad), Smad2 and Smad3. Activated R-Smads then form complexes with the co-Smad, Smad4, and this heteromeric Smad complex translocates to the nucleus to modulate specific target gene expression (Massague´, 1998) . TGFb target genes important for cell cycle regulation include c-myc, p21 CIP1 , p27 KIP1 and p15
INK4B
. The cell-cycledependent kinase inhibitor p15
INK4B is upregulated by TGFb to induce cell cycle arrest in G 1 (Hannon and Beach, 1994 ) and contributes to the antiproliferative effect of TGFb.
Resistance to the antiproliferative effect of TGFb occurs in numerous cancers, resulting from defects in the TGFb signaling pathway. Smad4 mutations are implicated in head and neck, lung and esophageal, gastric, breast, pancreatic and colorectal cancers (reviewed in Gold, 1999) . Mutations in Smad2 have been detected in colorectal and lung cancers (Riggins et al., 1997) . Defects in TbRII have been identified in hereditary nonpolyposis colorectal cancer, gastric, endometrial and head and neck cancers (reviewed in Gold, 1999) . TbR1 mutations have been identified in chronic lymphocytic leukemia, gastric and prostate cancer. In OC, TbRI, TbRII and Smad2 mutations have been described; however, it is unknown whether these mutations alter protein function (Lynch et al., 1998; Wang et al., 2000; Chen et al., 2001) . In contrast, we and others have previously shown that the TGFb signaling pathway is intact and functional in primary OC cells, and primary OC cells in culture stop growing in response to TGFb (Hurteau et al., 1994; Dunfield et al., 2002) . Although TGFb is antiproliferative to primary OC cells in culture, ovarian cancer cells in vivo are exposed to TGFb and yet continue to proliferate. Therefore, mechanisms must exist to inhibit TGFb signaling in OC cells permitting uncontrolled cellular proliferation. Numerous signaling pathways have been shown to converge with the TGFb signaling pathway to modulate its effects. Depending on the cell context, interferon gamma (IFNg), hepatocyte growth factor (HGF), epidermal growth factor (EGF) and oncogenic ras have all been shown to modulate TGFb signaling (de Caestecker et al., 1998; Kretzschmar et al., 1999; Ulloa et al., 1999; ten Dijke et al., 2000; Funaba et al., 2002) .
EGF receptor is expressed in 33-75% of ovarian tumors, and expression can be higher in ovarian tumors compared to normal ovary (reviewed in Auersperg et al., 2001) . We initiated studies to examine if EGF could modulate TGFb signaling in primary OC cells and found that EGF signaling abrogates the antiproliferative effect of TGFb in primary OC cells. The EGF modulation of TGFb signaling is not mediated at the level of R-Smad phosphorylation or Smad nuclear translocation, but at the level of specific target gene expression. EGF can reduce the TGFb-induced upregulation of p15 INK4B mRNA expression which likely decreases the antiproliferative effect of TGFb.
Results

EGF inhibits the antiproliferative effect of TGFb
Previously, we have shown that TGFb can inhibit proliferation of primary OC cells and loss of cell growth was correlated with an increase in p15 INK4B mRNA production (Dunfield et al., 2002) . To determine whether EGF could modulate the antiproliferative effect of TGFb, primary OC cells were grown in the presence of TGFb and EGF, alone and in combination, and proliferation was assessed by counting the cell number. All samples were grown in 1 : 1 mixture of M199/ MCDB105 supplemented with 10% fetal bovine serum (FBS). TGFb (T) (0.1 ng/ml or 1 ng/ml) inhibits proliferation of primary OC cells, whereas EGF (E)-(10 ng/ml) treated cells have a normal or higher than normal rate of proliferation compared to cells grown under normal growth conditions (untreated, UT; Figure 1 ). Cells treated with 0.1 ng/ml TGFb and 10 ng/ml EGF (ET) have a rate of proliferation significantly higher than TGFb-treated cells and similar to UT cells (Figure 1a) . Data are shown for OC samples OC5, OC15, OC17, OC19, and similar results were obtained for OC20, OC23 and OC28. In contrast, EGF is less effective at inhibiting the antiproliferative effect of 1 ng/ml TGFb (OC28 and OC23) ( Figure 1b and data not shown); however, EGF inhibition is effective for OC17 (Figure 1b) . 
EGF effect on TGFb-induced Smad2 and Smad3 phosphorylation
To determine whether EGF could modulate activity of the TGFb receptor complex, phosphorylation of the RSmads, Smad2 and Smad3, was determined by Western blot analysis. Results are shown for OC5 ( Figure 2 ) and similar results were found for OC14-OC17 (data not shown). Phosphorylation of Smad2 ( Figure 2a ) and Smad3 ( Figure 2b ) was strongly induced by 0.1 ng/ml TGFb compared to UT, whereas EGF (10 ng/ml) did not affect phosphorylation of Smad2 and Smad3. Cotreatment of cells with TGFb and EGF resulted in variable phospho-Smad2 and Smad3 levels comparable to TGFb treatment alone. In three independent experiments either no effect (Figure 2a ) or a decrease in Smad2 phosphorylation ( Figure 2c ) was observed in cotreated compared to TGFb-treated cells, and differential Smad phosphorylation was seen in the same cells of identical passage number. A complete blockade of Smad2 phosphorylation was never observed. Smad3 phosphorylation was typically unaffected by cotreatment (Figure 2b ), although slight decreases were observed in one experiment for two of the five OC samples.
Although it appears that total Smad2 levels are increased by TGFb treatment (Figure 2a ), this effect is because of the ability of the total Smad2 antibody to recognize both phosphorylated and unphosphorylated forms of Smad2, which can be seen when the two forms of Smad2 are further resolved (Figure 2c ). A similar effect was observed for Smad3 (data not shown).
EGF does not affect TGFb-induced nuclear localization of Smad2 and Smad3
Postreceptor activation of R-Smads leads to nuclear translocation; therefore, immunofluorescence was carried out to determine if EGF affected the TGFb-induced nuclear translocation of Smad2 and Smad3 in primary OC cells. Cellular localization of Smad2 and Smad3 in OC24 is shown (Figure 3a and b, respectively). UT cells have diffused nuclear and cytoplasmic localization of Smad2 and Smad3; however, treatment with TGFb (T) Figure 2 EGF effect on TGFb-induced upregulation of Smad2 and Smad3 phosphorylation. UT primary OC cells (OC5) have little or no phosphorylated Smad2 (P-Sm2) or Smad3 (P-Sm3) protein. TGFb (T) strongly induces phosphorylation of both Smad2 (a) and Smad3 (b). EGF (E) alone does not affect levels of Smad2 or Smad3 phosphorylation, whereas cells cotreated with TGFb and EGF (ET) have similar levels of phosphorylated Smad2 and Smad3. The apparent increase in total Smad2 levels (a) is actually a result of the total Smad2 antibody recognizing both phosphorylated and nonphosphorylated forms of Smad2, which can be seen when the proteins are further resolved (c). Actin protein levels were assessed to control for loading Treatment with TGFb (T) induces R-Smad nuclear translocation, and this is not inhibited by cotreatment with EGF (ET). EGF treatment (E) alone does not induce Smad2 or Smad3 nuclear translocation induces Smad2/Smad3 nuclear translocation (Figure 3 ). In addition, we observed that the level of Smad3 in the nucleus in UT cells appeared consistently higher than the level of nuclear Smad2. Treatment with EGF (E) has no observable effect on Smad nuclear translocation and cotreatment (ET) resulted in Smad nuclear translocation comparable to cells treated with TGFb alone (T). Similar results were obtained for OC5, OC15, and OC32. This result was verified by Western analysis of Smad2, examining nuclear and cytoplasmic protein extracts in response to the various treatments (data not shown).
EGF does not inhibit TGFb-induced Smad7 mRNA expression
Smad7 transcription is upregulated in response to TGFb signaling (Nakao et al., 1997) . In order to determine whether EGF could modulate the TGFb response at the transcriptional level, Northern analysis was done to examine Smad7 mRNA expression (Figure 4 ). UT samples express low levels of Smad7 mRNA, which is induced by TGFb treatment. EGF has been shown to upregulate Smad7 mRNA in mink lung epithelial cells (Afrakhte et al., 1998) ; however, EGF treatment either has no effect or only slightly increases Smad7 mRNA expression in primary OC cells. Cotreatment with EGF does not cause a decrease in TGFb-induced Smad7 mRNA levels. Results are shown for OC15-OC17, and similar data were observed for OC14 in two independent experiments, and for OC3, OC5 and OC15 in a single experiment (data not shown). All data were normalized to GAPDH mRNA expression levels.
EGF modulates TGFb-induced p15 INK4B mRNA expression
Since EGF can abrogate the antiproliferative effect of TGFb, we examined whether EGF could modulate TGFb-induced expression of p15 INK4B mRNA. p15 INK4B mRNA expression is shown for OC15 ( Figure 5 ) and similar results were found for OC5, OC14, OC16 and OC17 (data not shown). UT samples of asynchronously growing cells express little or no p15 INK4B mRNA, whereas TGFb strongly induces p15 INK4B mRNA expression ( Figure 5 ). EGF alone has no effect on p15 INK4B mRNA levels, however, cotreatment of EGF with TGFb reduces p15
INK4B mRNA levels below that of TGFb treatment alone. All data were normalized to GAPDH mRNA expression levels and are shown in Figure 5b . The expression levels and per cent reduction (39.1-61.4%) for cotreated samples (ET) compared to TGFbtreated samples are shown in Figure 5c .
Discussion
Modifications in TGFb signaling have been indicated in numerous types of cancers, including ovarian (Lynch et al., 1998; reviewed in Gold, 1999; Wang et al., 2000; Chen et al., 2001) ; however, we previously found that the TGFb signaling pathway was intact and functional in primary OC cells (Dunfield et al., 2002) . Since OC cells produce and are exposed to bioactive TGFb (reviewed in Auersperg et al., 2001) , inhibition of the antiproliferative effect of TGFb must exist to allow for the uncontrolled cellular proliferation of OC cells in vivo. We show that EGF inhibits the antiproliferative effect of TGFb in primary OC cells, and suggest that it may be one factor of many that can modulate TGFb cellular responses.
Alterations in TGFb signaling by EGF and related factors have been demonstrated in a number of studies, examining modulation of TGFb-induced R-Smad nuclear translocation by EGF, HGF or oncogenic ras. Indeed, oncogenic ras or EGF signaling activity can lead to inhibition of TGFb-induced Smad nuclear translocation in mouse mammary epithelial cells (Kretzschmar et al., 1999) . This is because of hyperphosphorylation of tyrosine residues in the linker region of Smad2 and (1998) show that HGF can phosphorylate Smad2, resulting in increased Smad2 nuclear translocation in a breast cancer cell line, and further speculate that EGF will have the same effect. In contrast, we find that EGF does not affect TGFb-induced Smad2 or Smad3 nuclear translocation in primary human OC cells, suggesting that crosstalk between the TGFb and EGF signaling pathways may be cell type dependent.
In order for R-Smads to translocate to the nucleus, they must be phosphorylated by an activated receptor complex. We found that EGF cotreatment did not result in loss of R-Smad phosphorylation, which is in agreement with our results that show that R-Smad nuclear translocation is unaffected by EGF cotreatment. Since we sometimes observe decreased levels of phosphorylated Smad2 and Smad3 with EGF cotreatment, we cannot rule out the possibility that EGF can modulate TGFb signaling at the receptor level. Our data strongly suggest that EGF has minimal effects on TGFb signaling at the level of R-Smad phosphorylation in OC cells.
Smad7 is an inhibitory Smad protein that can negatively regulate the TGFb pathway by inhibiting R-Smad phosphorylation by the activated receptor complex (Hayashi et al., 1997; Nakao et al., 1997) , and it has been shown that EGF can upregulate expression of Smad7 in mink lung epithelial cells (Afrakhte et al., 1998) . In comparison to the strong induction of Smad7 mRNA expression in response to TGFb, we observed minimal induction of Smad7 mRNA by EGF in primary OC cells, and thus, it is unlikely that EGF induces a negative effect on TGFb signaling via Smad7. Indeed, our results show that EGF cotreatment does not affect TGFb signaling activity from the receptor to the nucleus.
In studies of TGFb and EGF on normal bovine OSE cells, Vigne et al. (1994) found that EGF stimulated proliferation of bovine OSE, and this effect was partially decreased by TGFb cotreatment. They did not observe an effect of TGFb alone on bovine OSE proliferation and suggest that TGFb inhibits the mitogenic effect of EGF. These results were obtained using a [
3 H]thymidine incorporation assay after 24 h of treatment. The lack of a TGFb response is likely because of the short time course of treatment or possibly species differences. In the present study, primary OC cells were treated and counted over a period of 7 days, and the maximal responses were seen at the later time points. Although the possibility exists that TGFb inhibits the mitogenic effect of EGF, our observation that EGF inhibits the TGFb-induced upregulation of p15 INK4B mRNA expression strongly suggests that EGF inhibits the antiproliferative effect of TGFb in human OC cells.
EGF can inhibit the antiproliferative effect of 0.1 ng/ ml TGFb in all primary OC cells tested (n ¼ 7); however, inhibition of 1 ng/ml TGFb by EGF is less consistent. This is not surprising, considering other studies have shown differential effects of TGFb and EGF on Smad nuclear translocation in mink lung epithelial cells depending on the dose of TGFb (Kretzschmar et al., 1999) . Although a trend for EGF inhibition of the antiproliferative effect of 1 ng/ml TGFb was seen, this effect was not statistically significant, and appeared to be cell sample and passage number dependent.
OC cells are exposed to and synthesize TGFb. In OC patient ascites fluid, we determined the mean concentration of active TGFb to be 2.3 ng/ml and total TGFb (active þ latent) concentration to be 7.5 ng/ml (n ¼ 11) (LD Dunfield and MW Nachtigal, unpublished results). Despite the apparently high concentration of active TGFb present in ascites fluid, the level of signaling activity, determined by Smad2 phosphorylation, is much lower when compared to a similar concentration of exogenously added recombinant TGFb. This suggests that signaling activity of some TGFb in ascites fluid may be inhibited prior to R-Smad phosphorylation, and the remaining TGFb that can signal may be inhibited further downstream by factors such as EGF, to reduce the TGFb growth-inhibitory effect in vivo.
Although we show that EGF can partially inhibit the antiproliferative effect of TGFb in OC cells, other signaling pathways may also contribute to abrogation of the TGFb signal. HGF and oncogenic ras have been shown to alter TGFb signaling in human breast cancer cells and mouse mammary epithelial cells, respectively (de Caestecker et al., 1998; Kretzschmar et al., 1999) . In addition, IFNg can inhibit nuclear translocation of Smad3 in a mutant human fibrosarcoma cell line (Ulloa et al., 1999) , which could interfere with TGFb transcriptional responses. These factors may also be present and act to inhibit TGFb signaling in vivo, contributing to uncontrolled cellular proliferation. Indeed, HGF was found to be present in ascites fluid of OC patients (Sowter et al., 1999) .
A possible mechanism for EGF inhibition of the TGFb-induced upregulation of p15 INK4B expression is via EGF stabilization of the Smad transcriptional corepressor TGIF. EGF signaling phosphorylates TGIF, resulting in TGIF stabilization and interaction with Smad2 (Lo et al., 2001) . TGIF binding to Smad2 induces formation of a complex at TGFb target gene promoters and inhibition of gene expression through the recruitment of histone deacetylases (HDACs) (Wotton et al., 1999) . Indeed, overexpression of TGIF in HaCaT cells has been shown to inhibit p15 INK4B mRNA expression (Lo et al., 2001) . We found that TGIF mRNA is expressed in primary OC cells (LD Dunfield and MW Nachtigal, unpublished results) . Future work will examine whether stabilization of TGIF results in recruitment of HDAC to the p15 INK4B promoter and inhibition of TGFb-induced p15 INK4B mRNA expression in primary OC cells.
Although we find that the TGFb signaling pathway is intact in our population of primary OC cells, mechanisms must exist to alter cellular responses to TGFb and contribute to uncontrolled cellular proliferation. We show that EGF hinders the TGFb-induced upregulation of p15
INK4B
, and this likely contributes to inhibition of the antiproliferative effect of TGFb in primary OC cells. In vivo, the presence of additional growth factors may prevent TGFb cellular responses, and it is likely that a combination of factors act to modulate cellular responses. Inhibition of these signaling pathways may therefore help to restore the antiproliferative effect of TGFb, and therapeutics that block these other pathways may be important treatment options for OC patients.
Materials and methods
Primary human OC cells
Institutional approval for research with human materials was received prior to the initiation of these studies (QEII Health Sciences Centre, Research Ethics Committee, #QE-RS-99-016). Primary human OC cells were isolated from ascites fluid obtained from chemotherapeutically naı¨ve stage III or stage IV OC patients. The majority of the samples obtained were diagnosed as serous adenocarcinoma. Ascites fluid was mixed 1 : 1 with MCDB105 (Sigma)/M199 (Invitrogen) supplemented with 10% FBS (CanSera) and penicillin/streptomycin. Cells were allowed to adhere for 2-3 days, at which time cells were washed with PBS, and fed fresh growth medium.
Growth curves
Primary human OC cells (OC5, OC15, OC17, OC19, OC20, OC23, OC28) were plated (4 Â 10 4 cells/well) in six-well plates in normal growth medium (MCDB105/M199 supplemented with 10% FBS) on day 0. On days 1 and 4, cells were treated with 0.1 or 1 ng/ml TGFb and 10 ng/ml EGF in normal growth medium, alone and in combination. Cells were counted using a hemacytometer for a 7 day period. The data are representative of at least three independent experiments.
Western analysis
Primary OC cells (OC5, OC14-OC17) were grown to 70-90% confluence and serum starved (normal growth medium supplemented with 0.2% FBS) overnight prior to treatment. Cells were treated with 0.1 ng/ml TGFb and 10 ng/ml EGF for 1 h. Protein was extracted by lysing cells in buffer containing 50 mm HEPES, 150 mm NaCl, 10% glycerol, 1.5 mm MgCl 2 , 1 mm EGTA, 1 mm sodium orthovanadate, 10 mm sodium pyrophosphate, 10 mm sodium fluoride, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mm PMSF and 1 Â protease inhibitor cocktail (Roche Molecular Biochemicals). Protein was quantitated using Bradford analysis. Whole-cell protein (20 mg) was separated on 12% polyacrylamide gels, transferred to nitrocellulose membranes, and protein was detected using specific antibodies. Anti-Smad2 and anti-Smad3 (Zymed Laboratories Inc, South San Francisco, CA, USA), anti-phospho-Smad2 (Upstate biotechnology Inc, Lake Placid, NY, USA), anti-phospho-Smad3 (gift from Dr Edward Leof, Mayo Clinic Cancer Center) and anti-Actin (Sigma, St Louis, MO, USA) were used to detect protein expression using enhanced chemiluminescence (Perkin-Elmer corp., Markham, ON, Canada). Signals were quantified by densitometry of autoradiographs. The data shown are representative of two independent experiments.
Immunofluorescence
Primary OC cells (OC5, OC15, OC24, OC32) were plated on glass coverslips in 12-well plates at a density of 4 Â 10 4 cells/ well and allowed to adhere for 48 h. Cells were then serum starved overnight and the following day, cells were treated with TGFb (1 ng/ml) and EGF (10 ng/ml) for 1 h. Cells were fixed with 4% paraformaldehyde, blocked in 5% horse serum and incubated with primary antibody overnight at 41C. Rabbit anti-Smad2 and anti-Smad3 antibodies were used to detect cellular localization of Smad2 and Smad3 protein. Fluorescent conjugated anti-rabbit Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA) was used to detect protein expression and intracellular localization by immunofluorescence. Data are representative of two independent experiments.
Northern analysis
Primary OC cells were grown to 70-90% confluence, and treated with 0.1 ng/ml TGFb and 10 ng/ml EGF for 4 h. Total RNA was isolated from primary OC cells using the Genelute Mammalian Total RNA kit (Sigma-Aldrich, Oakville, ON, Canada). Total RNA (10 mg) was separated on 1.5% formaldehyde gels and transferred to Brightstar plus membrane (Ambion Inc., Austin, TX, USA). Blots were incubated with 1 Â 10 6 cpm/ml probe overnight. cDNA probes (GAPDH and Smad7) were hybridized overnight at 421C and washed at 421C in wash solution (0.1% SDS, 0.1 Â SSC). cRNA probes (p15
INK4B
) were hybridized overnight at 601C and washed for 2 Â 1 h at 651C and 15 min at 751C in wash solution (0.1% SDS, 0.1 Â SSC, 1 mm EDTA). Signals were visualized by autoradiography and loading controlled by normalization to the GAPDH signal. Signals were quantified by densitometry of autoradiographs. Data shown are representative of two independent experiments.
Statistical analysis
Growth curve statistical analysis was performed using a repeated measures two-way ANOVA with Tukey's post hoc test (Po0.05).
